ArticlePloS one2012
Molecular diagnosis of Usher syndrome: application of two different next generation sequencing-based procedures.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Prevalence of mutations in inherited retinal diseases: A comparison between the United States and India.Molecular genetics & genomic medicine · 2020Article
- Aberrant Splicing Events Associated toGenes · 2019Article
- Genetic Screening of the Usher Syndrome in Cuba.Frontiers in genetics · 2019Article
- Genetic analysis of Tunisian families with Usher syndrome type 1: toward improving early molecular diagnosis.Molecular vision · 2016Article
- Whole-exome sequencing identifies USH2A mutations in a pseudo-dominant Usher syndrome family.International journal of molecular medicine · 2015Article
- Targeted next generation sequencing for molecular diagnosis of Usher syndrome.Orphanet journal of rare diseases · 2014Article
- Screening for single nucleotide variants, small indels and exon deletions with a next-generation sequencing based gene panel approach for Usher syndrome.Molecular genetics & genomic medicine · 2014Article
- Exome sequencing greatly expedites the progressive research of Mendelian diseases.Frontiers of medicine · 2014Review
- Novel deletions involving the USH2A gene in patients with Usher syndrome and retinitis pigmentosa.Molecular vision · 2014Article
- Experience of targeted Usher exome sequencing as a clinical test.Molecular genetics & genomic medicine · 2014Article
- Combined genetic and high-throughput strategies for molecular diagnosis of inherited retinal dystrophies.PloS one · 2014Article
- MYO7A and USH2A gene sequence variants in Italian patients with Usher syndrome.Molecular vision · 2014Article
- Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome.Genomics · 2013Article
- Exome sequencing of index patients with retinal dystrophies as a tool for molecular diagnosis.PloS one · 2013Article
- Next generation sequencing (NGS) strategies for the genetic testing of myopathies.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Usher syndrome (USH) is a clinically and genetically heterogeneous disorder characterized by visual and hearing impairments. Clinically, it is subdivided into three subclasses with nine genes identified so far. In the present study, we investigated whether the currently available Next Generation Sequencing (NGS) technologies are already suitable for molecular diagnostics of USH. We analyzed a total of 12 patients, most of which were negative for previously described mutations in known USH genes upon primer extension-based microarray genotyping. We enriched the NGS template either by whole exome capture or by Long-PCR of the known USH genes. The main NGS sequencing platforms were used: SOLiD for whole exome sequencing, Illumina (Genome Analyzer II) and Roche 454 (GS FLX) for the Long-PCR sequencing. Long-PCR targeting was more efficient with up to 94% of USH gene regions displaying an overall coverage higher than 25×, whereas whole exome sequencing yielded a similar coverage for only 50% of those regions. Overall this integrated analysis led to the identification of 11 novel sequence variations in USH genes (2 homozygous and 9 heterozygous) out of 18 detected. However, at least two cases were not genetically solved. Our result highlights the current limitations in the diagnostic use of NGS for USH patients. The limit for whole exome sequencing is linked to the need of a strong coverage and to the correct interpretation of sequence variations with a non obvious, pathogenic role, whereas the targeted approach suffers from the high genetic heterogeneity of USH that may be also caused by the presence of additional causative genes yet to be identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.